| Literature DB >> 17575261 |
Sonia Messina1, Anna Mazzeo, Alessandra Bitto, M'hammed Aguennouz, Alba Migliorato, Maria G De Pasquale, Letteria Minutoli, Domenica Altavilla, Lorena Zentilin, Mauro Giacca, Francesco Squadrito, Giuseppe Vita.
Abstract
Vascular endothelial growth factor (VEGF) is a major regulator of physiological and pathological angiogenesis. Recently it was reported that the delivery of VEGF using recombinant adeno-associated virus (rAAV) vectors reduces muscle damage and promotes muscle regeneration in different experimental models of muscle necrosis. We demonstrate that intramuscular administration of rAAV-VEGF improved pathophysiology of the mdx mouse, a model of Duchenne muscular dystrophy (DMD). One month after injection, rAAV-VEGF-treated muscles showed augmented expression of VEGF and immunolocalization of its receptor, VEGFR-2. VEGF-treated mdx mice showed increased forelimb strength and strength normalized to weight. Treatment reduced necrotic fibers area and increased regenerating fibers area with an augmented number of myogenin-positive satellite cells and myonuclei, and of developmental myosin heavy chain-positive fibers. Only the regenerating area showed increased capillary density. This study provides novel evidence of a VEGF beneficial effect in mdx mice that is exerted mainly by a proregenerative and angiogenic effect. It opens new therapeutic prospectives in DMD and other types of muscular disorders.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17575261 DOI: 10.1096/fj.07-8459com
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191